Pulse Biosciences (PLSE) – Investment Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Pulse Biosciences (NASDAQ: PLSE):

• 8/29/2026 – Pulse Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/17/2026 – Pulse Biosciences is now covered by Needham & Company LLC. They set a “buy” rating and a $58.00 price target on the stock.
• 8/10/2026 – Pulse Biosciences was given a new $45.00 price target by Mizuho.
• 8/10/2026 – Pulse Biosciences had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $43.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Pulse Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/28/2026 – Pulse Biosciences had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 7/28/2026 – Pulse Biosciences was given a new $35.00 price target by Oppenheimer Holdings, Inc..
• 7/17/2026 – Pulse Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other news, COO Liane Rae Teplitsky purchased 1,034 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were bought at an average price of $48.35 per share, for a total transaction of $49,993.90. Following the completion of the transaction, the chief operating officer owned 2,070 shares in the company, valued at $100,084.50. This represents a 99.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 74.00% of the company’s stock.

Get Pulse Biosciences Inc alerts:

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

Featured Stories

• Five stocks we like better than Pulse Biosciences
• Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
• Insiders Are Betting Big on These 3 Healthcare Stocks
• 3 Stocks for Investors Who Still Believe Cash Is King
• Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason

Receive News & Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.